| 2.94 -2.97 (-50.25%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.73 | 1-year : | 10.2 |
| Resists | First : | 7.48 | Second : | 8.73 |
| Pivot price | 2.48  |
|||
| Supports | First : | 3.14 | Second : | 0.46 |
| MAs | MA(5) : | 6.01 |
MA(20) : | 2.04 |
| MA(100) : | 1.07 |
MA(250) : | 1.64 |
|
| MACD | MACD : | 1.2 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 76.5 |
D(3) : | 77.5 |
| RSI | RSI(14): 69.3  |
|||
| 52-week | High : | 7.48 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALUR ] has closed below upper band by 19.8%. Bollinger Bands are 957.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.56 - 5.59 | 5.59 - 5.62 |
| Low: | 0.54 - 0.55 | 0.55 - 0.55 |
| Close: | 5.49 - 5.56 | 5.56 - 5.6 |
Allurion Technologies Inc. is dedicated to combating obesity by offering a comprehensive weight management ecosystem designed for individuals with excess weight. At the core of its solution is the Allurion Program, featuring the innovative Allurion Balloon – a novel, non-surgical, swallowable intragastric device engineered to promote significant weight loss. This program is further enhanced by the Allurion Virtual Care Suite, which provides sophisticated AI-powered remote patient monitoring, a specialized behavior modification curriculum, encrypted messaging capabilities, and virtual telehealth consultations. The firm's main operational base is located in Natick, Massachusetts.
Mon, 22 Jun 2026
Allurion Technologies Inc (ALUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Thu, 18 Jun 2026
Allurion Technologies (ALUR) Announces 1-for-15 Reverse Stock Sp - GuruFocus
Wed, 17 Jun 2026
Allurion Advances Plan to Re-List - Business Wire
Wed, 17 Jun 2026
Allurion Technologies Inc (ALUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fri, 15 May 2026
ALUR: Q1 2026 saw a 47% revenue decline, FDA approval, and NYSE delisting amid liquidity risks - TradingView
Fri, 15 May 2026
ALUR Financials: Income Statement, Balance Sheet & Cash Flow | ALLURION TECHNOLOGIES INC - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 15 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 476 (K) |
| Shares Short P.Month | 490 (K) |
| EPS | -3.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.2 |
| Profit Margin | -264.8 % |
| Operating Margin | -126.6 % |
| Return on Assets (ttm) | -66.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -47.3 % |
| Gross Profit (p.s.) | 0.44 |
| Sales Per Share | 0.83 |
| EBITDA (p.s.) | -1.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -1.41 |
| PEG Ratio | 0 |
| Price to Book value | -1.07 |
| Price to Sales | 6.61 |
| Price to Cash Flow | -3.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|